Bone-Gla protein (BGP)/carboxyterminal cross-linked telopeptide of type I collagen (ICTP) ratio in the assessment of bone turnover in adults with childhood onset GH deficiency

A. Sartorio, A. Conti, M. Monzani, F. Morabito

Research output: Contribution to journalArticle

Abstract

In this study we evaluated serum bone Gla protein (BGP)/carboxyterminal cross-linked telopeptide of type I collagen (ICTP) ratio, which reflects the balance between bone formation and bone resorption, in a group of adults with childhood onset GH deficiency (GHD) before, during and after the withdrawal of recombinant GH therapy. Before treatment, mean BGP/ICTP ratio of patients was significantly lower (p <0.05) than in normals, thus suggesting the prevalence of bone resorption activity on bone formation. GH treatment significantly (p <0.05) increased BGP/ICTP ratio; during treatment the ratio was not different from that recorded in normals, being however the expression of an overall stimulation of the two components of bone turnover (formation and resorption). It is noteworthy that after 6 months from the withdrawal of GH treatment, BGP/ICTP ratio remained similar to those observed during treatment and in normals, in spite of a reduction of BGP and ICTP levels. This finding suggests that a normal equilibrium between bone formation and resorption favourably lasts after the withdrawal of treatment; the effects exerted by six months of GH treatment on BGP/ICTP ratio were no longer evident 9 months after its withdrawal. In conclusion, the use of the BGP/ICTP ratio might be usefully employed in monitoring the course of clinical disorders characterized by imbalance between bone formation and resorption, being also better studied suited to assess the effects of treatment on bone turnover.

Original languageEnglish
Pages (from-to)91-96
Number of pages6
JournalActa Medica Auxologica
Volume26
Issue number2-3
Publication statusPublished - 1994

Fingerprint

Bone Remodeling
Osteocalcin
Collagen Type I
Bone Resorption
Osteogenesis
Therapeutics
Blood Proteins
Bone and Bones

Keywords

  • adulthood
  • bone Gla protein
  • bone turnover
  • GH deficiency
  • GH treatment
  • telopeptide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{260eaab0f73348a49080463476e371a3,
title = "Bone-Gla protein (BGP)/carboxyterminal cross-linked telopeptide of type I collagen (ICTP) ratio in the assessment of bone turnover in adults with childhood onset GH deficiency",
abstract = "In this study we evaluated serum bone Gla protein (BGP)/carboxyterminal cross-linked telopeptide of type I collagen (ICTP) ratio, which reflects the balance between bone formation and bone resorption, in a group of adults with childhood onset GH deficiency (GHD) before, during and after the withdrawal of recombinant GH therapy. Before treatment, mean BGP/ICTP ratio of patients was significantly lower (p <0.05) than in normals, thus suggesting the prevalence of bone resorption activity on bone formation. GH treatment significantly (p <0.05) increased BGP/ICTP ratio; during treatment the ratio was not different from that recorded in normals, being however the expression of an overall stimulation of the two components of bone turnover (formation and resorption). It is noteworthy that after 6 months from the withdrawal of GH treatment, BGP/ICTP ratio remained similar to those observed during treatment and in normals, in spite of a reduction of BGP and ICTP levels. This finding suggests that a normal equilibrium between bone formation and resorption favourably lasts after the withdrawal of treatment; the effects exerted by six months of GH treatment on BGP/ICTP ratio were no longer evident 9 months after its withdrawal. In conclusion, the use of the BGP/ICTP ratio might be usefully employed in monitoring the course of clinical disorders characterized by imbalance between bone formation and resorption, being also better studied suited to assess the effects of treatment on bone turnover.",
keywords = "adulthood, bone Gla protein, bone turnover, GH deficiency, GH treatment, telopeptide",
author = "A. Sartorio and A. Conti and M. Monzani and F. Morabito",
year = "1994",
language = "English",
volume = "26",
pages = "91--96",
journal = "Acta Medica Auxologica",
issn = "0001-6004",
publisher = "Istituto Auxologico Italiano",
number = "2-3",

}

TY - JOUR

T1 - Bone-Gla protein (BGP)/carboxyterminal cross-linked telopeptide of type I collagen (ICTP) ratio in the assessment of bone turnover in adults with childhood onset GH deficiency

AU - Sartorio, A.

AU - Conti, A.

AU - Monzani, M.

AU - Morabito, F.

PY - 1994

Y1 - 1994

N2 - In this study we evaluated serum bone Gla protein (BGP)/carboxyterminal cross-linked telopeptide of type I collagen (ICTP) ratio, which reflects the balance between bone formation and bone resorption, in a group of adults with childhood onset GH deficiency (GHD) before, during and after the withdrawal of recombinant GH therapy. Before treatment, mean BGP/ICTP ratio of patients was significantly lower (p <0.05) than in normals, thus suggesting the prevalence of bone resorption activity on bone formation. GH treatment significantly (p <0.05) increased BGP/ICTP ratio; during treatment the ratio was not different from that recorded in normals, being however the expression of an overall stimulation of the two components of bone turnover (formation and resorption). It is noteworthy that after 6 months from the withdrawal of GH treatment, BGP/ICTP ratio remained similar to those observed during treatment and in normals, in spite of a reduction of BGP and ICTP levels. This finding suggests that a normal equilibrium between bone formation and resorption favourably lasts after the withdrawal of treatment; the effects exerted by six months of GH treatment on BGP/ICTP ratio were no longer evident 9 months after its withdrawal. In conclusion, the use of the BGP/ICTP ratio might be usefully employed in monitoring the course of clinical disorders characterized by imbalance between bone formation and resorption, being also better studied suited to assess the effects of treatment on bone turnover.

AB - In this study we evaluated serum bone Gla protein (BGP)/carboxyterminal cross-linked telopeptide of type I collagen (ICTP) ratio, which reflects the balance between bone formation and bone resorption, in a group of adults with childhood onset GH deficiency (GHD) before, during and after the withdrawal of recombinant GH therapy. Before treatment, mean BGP/ICTP ratio of patients was significantly lower (p <0.05) than in normals, thus suggesting the prevalence of bone resorption activity on bone formation. GH treatment significantly (p <0.05) increased BGP/ICTP ratio; during treatment the ratio was not different from that recorded in normals, being however the expression of an overall stimulation of the two components of bone turnover (formation and resorption). It is noteworthy that after 6 months from the withdrawal of GH treatment, BGP/ICTP ratio remained similar to those observed during treatment and in normals, in spite of a reduction of BGP and ICTP levels. This finding suggests that a normal equilibrium between bone formation and resorption favourably lasts after the withdrawal of treatment; the effects exerted by six months of GH treatment on BGP/ICTP ratio were no longer evident 9 months after its withdrawal. In conclusion, the use of the BGP/ICTP ratio might be usefully employed in monitoring the course of clinical disorders characterized by imbalance between bone formation and resorption, being also better studied suited to assess the effects of treatment on bone turnover.

KW - adulthood

KW - bone Gla protein

KW - bone turnover

KW - GH deficiency

KW - GH treatment

KW - telopeptide

UR - http://www.scopus.com/inward/record.url?scp=0028581373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028581373&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 91

EP - 96

JO - Acta Medica Auxologica

JF - Acta Medica Auxologica

SN - 0001-6004

IS - 2-3

ER -